Analysts expect that NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) will post ($0.04) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for NovaBay Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.08). NovaBay Pharmaceuticals reported earnings per share of $0.02 during the same quarter last year, which would suggest a negative year-over-year growth rate of 300%. The firm is scheduled to report its next quarterly earnings results on Tuesday, March 19th.

On average, analysts expect that NovaBay Pharmaceuticals will report full-year earnings of ($0.31) per share for the current fiscal year. For the next financial year, analysts expect that the company will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.35) to ($0.32). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for NovaBay Pharmaceuticals.

Shares of NBY traded down $0.05 during trading hours on Wednesday, reaching $1.14. The company’s stock had a trading volume of 6,800 shares, compared to its average volume of 12,799. NovaBay Pharmaceuticals has a 1-year low of $0.97 and a 1-year high of $4.54.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.